New Two-Drug attack on inherited Alzheimer's aims to slow brain decline
NCT ID NCT05269394
Summary
This trial is testing whether adding an experimental anti-tau drug (E2814) to an approved anti-amyloid drug (lecanemab) can better slow the progression of Alzheimer's disease in people who have a specific genetic mutation that causes it. It involves about 200 participants, some with early symptoms and some without, who will receive the drug combination or a placebo plus lecanemab for up to four years. The main goal is to see if the combination reduces harmful tau protein spread in the brain and slows cognitive decline more than the anti-amyloid drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068, United States
-
Alzheimer's Research Australia
Melbourne, Victoria, 3010, Australia
-
Azienda Ospedaliera Universitaria Careggi
Florence, 50134, Italy
-
Brain Research Center
Amsterdam, 1081 GM, Netherlands
-
Butler Hospital
Providence, Rhode Island, 02096, United States
-
CHU de Quebec - Hôpital de l' Enfant Jésus
Québec, G1J 1Z4, Canada
-
CHU de Rouen - Hôpital Charles Nicolle
Rouen, Seine Maritime, 76031, France
-
CHU de Toulouse - Hôpital Purpan
Toulouse, Haute Garonne, 31059, France
-
Emory University
Atlanta, Georgia, 30329, United States
-
Groupe Hospitalier Pitie-Salpetriere
Paris, Paris, 69677, France
-
Grupo de Neurociencias Sede de la Universidad de Antioquia
Medellín, Colombia
-
Hopital Neurologique Pierre Wertheimer
Bron, Rhone, 69677, France
-
Hopital Roger Salengro - CHU Lille
Lille, Nord, 59037, France
-
Hospital Clínic I Provincial de Barcelona
Barcelona, 8036, Spain
-
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, 05403-000, Brazil
-
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Brescia, 25125, Italy
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Mexico City, Mexico City, 14269, Mexico
-
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
Ciudad Autonoma de Buenos Aire, C1428AQK, Argentina
-
Kerwin Research Center,
Dallas, Texas, 75231, United States
-
LMU-Campus Grosshadern
Munich, Bavaria, 81377, Germany
-
McGill Center for Studies in Aging
Verdun, Quebec, H4H 1R3, Canada
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia
-
St Vincent's University Hospital
Dublin, DUBLIN 4, Ireland
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
The National Hospital for Neurology and Neurosurgery
London, Greater London, WC1B 3BG, United Kingdom
-
USC Keck School of Medicine
Los Angeles, California, 90033, United States
-
Universitaetsklinikum Tubingen
Tübingen, Baden-Wurttemberg, 72076, Germany
-
University of Alabama in Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Diego Medical Center
La Jolla, California, 92037, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
University of Puerto Rico, School of Medicine
San Juan, 00936, Puerto Rico
-
University of Tokyo Hospital
Bunkyō City, Tokyo-To, 113-8655, Japan
-
University of Washington
Seattle, Washington, 98195, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.